TheraRadar
Data updated: May 26, 2026

XEGLYZE (abametapir)

First-in-Class
Dermatology Approved 2020-07-24
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
5
Years on Market

Details

Status
Discontinued
First Approved
2020-07-24
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
LOTION

Companies

LNHC
Active Ingredient: ABAMETAPIR

XEGLYZE Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2020 to 2022
Jul 2022 SUPPL
Label · Labeling
FDA Letter Label
Jul 2020 ORIGINAL
New Drug · Type 1 - New Molecular Entity
FDA Letter Label

What XEGLYZE Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XEGLYZE FDA Label Details

View full patent landscape →
2 OB patents · 2 families · 28 international docs across 9 countries

XEGLYZE Patents & Exclusivity

Latest Patent: Dec 2034

Patents (2 active)

US10292389 Expires Dec 17, 2034
US7812163 Expires Oct 28, 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for XEGLYZE

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2034
  • • 2 active patents

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA206966 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.